XBIO
- Xenetic Biosciences, Inc.
()
Overview
Company Summary
Xenetic Biosciences, Inc. (XBIO) is a biopharmaceutical company focused on leveraging its proprietary drug development platforms to discover and develop innovative therapeutics for various medical conditions. The company combines advanced genetic engineering technology and biologic drug development expertise to create next-generation medicines.
Xenetic Biosciences has an extensive portfolio of biologic drug candidates that target different therapeutic areas, including oncology, hematology, and infectious diseases. These drug candidates are designed to address unmet medical needs and improve patient outcomes.
One of the core technologies employed by Xenetic Biosciences is PolyXen�, a proprietary platform that uses a polysialic acid polymer to enhance the pharmacokinetic properties of existing biologic drugs. By attaching this polymer to a drug, Xenetic is able to extend its half-life, improve its stability, and potentially enhance its effectiveness.
In addition to PolyXen�, Xenetic Biosciences also utilizes proprietary drug delivery technologies, such as Virexxa� and Oncohist�, which enable targeted drug delivery to specific cells or tissues. These platforms aim to increase drug efficacy while minimizing potential side effects.
The company also pursues collaborations and partnerships with leading pharmaceutical companies to leverage its technologies and expertise in advancing drug development programs. By forming strategic alliances, Xenetic Biosciences aims to expedite the clinical development and commercialization of its drug candidates.
Overall, Xenetic Biosciences is focused on developing innovative biologic drugs by leveraging its proprietary platforms and collaborating with industry partners, with the ultimate goal of improving patient outcomes and addressing unmet medical needs.